We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
With the future of its withdrawn multiple sclerosis drug Tysabri still unclear, Biogen Idec plans to lay off 650 employees, sell its San Diego manufacturing plant and channel the savings from those moves into drug development.
Biogen Idec and Elan’s multiple sclerosis drug Tysabri may pose other health risks in addition to its links to a deadly brain disease, according to an analyst who reviewed FDA data on the drug.
Health Canada has agreed to allow Shire Pharmaceuticals’ attention-deficit/hyperactivity disorder (ADHD) treatment Adderall XR back on the market — a move that comes roughly six months after the agency suspended sales of the drug because of safety concerns.
Merck plans to appeal an Aug. 19 verdict returned by a Texas jury that found the company liable for the death of a man who took Merck's now-withdrawn arthritis pain drug Vioxx.